# Medline Inc. (MDLN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $36.59, market value $49.2 billion.

## Valuation
- **P/E (trailing): 45.7×**. Medline Inc. trades at 45.7× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 23.1×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 1.7×**. Each dollar of revenue is priced at 1.7×.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 19.7×**. Enterprise value is 19.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 3.2%** (5-yr avg 3.8%). Free cash flow equals 3.2% of the market value, in line with its five-year average of 3.8%.
- **Earnings yield: 2.2%**. The inverse of the P/E: 2.2% of the price is earned each year.

## Profitability
- **Gross margin: 27.3%**. Medline Inc. keeps 27.3% of revenue after the direct cost of what it sells.
- **Operating margin: 7.1%**. 7.1% of revenue is left after running the business.
- **Net margin: 4.1%**. 4.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.8%**. 10.8% on shareholders' equity is solid.
- **Return on invested capital: 7.5%**. Return on all capital, debt included, is 7.5%.
- **Return on assets: 2.7%**. Each dollar of assets produces 2.7% of profit.

## Growth
- **Revenue growth (1 yr): 11.5%**. Revenue grew 11.5% over the last year.

## Financial health
- **Debt to equity: 1.17**. Debt is 1.17 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 3.5×**. It would take 3.5 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 2.86**. A Z-score of 2.86 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Medline Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (25 analysts). 25 analysts cover Medline Inc.; the consensus is buy, with an average price target of $44.60 (+22% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -28.1%** (12.6% above the low). Trading 28% below its 52-week high.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.60** (volatility 46%). Beta of 0.60 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MDLN · Page: https://foliofundamentals.com/stocks/mdln

Not investment advice.